Gossamer Bio, Inc.

GOSS • Biotechnology

$0.18

▼ -0.00 (-0.17%)

Precio actual

ResultadosÚltimo reporte: 31 mar 2026

PERFIL DÉBILDébilConfianza: 70%

Perfil cuantitativo — no constituye una recomendación de inversión.

Perfil cuantitativo — no constituye una recomendación de inversión.Metodología

Tesis del análisis: Perfil histórico débil. La evidencia actual no sostiene una relación riesgo/retorno favorable.

Capitalización

$41.04M

Crecimiento

—

Flujo de caja

0/5

Tendencia

Negative

Evidencia

Liquidez saludable · 2.64Tendencia de crecimiento negativaRentabilidad débil

Datos financieros hasta: 31 mar 2026, 12:00 a.m. UTCÚltima actualización de earnings: 18 may 2026, 12:00 a.m. UTCÚltima actualización del perfil: 5 ago 2026, 2:36 p.m. UTC

Resumen de la compañía

Valoración, calidad, fortaleza financiera, momentum y datos de analistas.

Price$0.18

Change-0.17%

Shares Out234.14M

Market Cap$41.04M

Enterprise Value$141.55M

52W Range0.14 - 3.87

Beta2.01

P/E-0.23

P/S0.74

P/B-0.25

P/FCF-0.24

EV/Sales2.55

Price$0.18

Change-0.17%

Shares Out234.14M

Market Cap$41.04M

Enterprise Value$141.55M

52W Range0.14 - 3.87

Beta2.01

P/E-0.23

P/S0.74

P/B-0.25

P/FCF-0.24

EV/Sales2.55

EV/EBITDA-0.83

EV/FCF-0.83

Earnings Yield-439.52%

FCF Yield-414.96%

Dividend Yield0.00%

Gross Margin97.93%

Oper. Margin-3.37%

Profit Margin-3.51%

Debt/Eq-1.65

Current Ratio2.64

Quick Ratio2.64

Target$3.47

Target Upside1879.46%

Target Median$3.00

Target Range0.30 - 9.00

Volume11.30M

Avg Volume11.93M

EPS Surprise-0.03

ADN de inversión

Qué tan fuerte luce esta compañía para inversionistas de largo plazo

de 100

Calidad del negocio

Márgenes, ventaja competitiva, retornos

22/100

Fortaleza financiera

Deuda, caja, estabilidad

70/100

Potencial de crecimiento

Ingresos y expansión

20/100

Atractivo del precio

Barata o cara hoy

20/100

Por qué este puntaje▼

Liquidez saludable · 2.64Tendencia de crecimiento negativaRentabilidad débil

Analyst view

Analyst sentiment and price target

GOSS

Analyst sentiment

Based on 17 analyst votes · 2026-09-05

74/100

Bullish

Hold

Bearish

Precio objetivo

2026-07-02

Bajo

$0.30

Promedio

$0.77

Mediana

$1.00

Alto

$1.00

Resumen de la compañía

IPO: 2/8/2019

Industria: Biotechnology

P/B i: -0.25

Deuda / Patrimonio i: -1.65

Margen operativo: -336.81%

Margen neto: -351.49%

ROE i: -

ROIC: -

Salud financiera

Puntaje14 / 20

Deuda / Patrimonio: -1.65

Ratio corriente: 2.64

Ratio rápido: 2.64

Estado: Good

Transacciones internas

Actividad reciente de ejecutivos e insiders

⚠ 4 venta interna de alto volumens detectadas

Nathan Steven D

Transacción: 06/04/2026

COMPRA

Cambio

+115,000

Precio

$0.18

Presentación

06/05/2026

Tipo

COMPRA

Milligan Sandra

Transacción: 06/04/2026

COMPRA

Cambio

+115,000

Precio

$0.18

Presentación

06/05/2026

Tipo

COMPRA

Cox Russell J.

Transacción: 06/04/2026

COMPRA

Cambio

+115,000

Precio

$0.18

Presentación

06/05/2026

Tipo

COMPRA

Insider	Tipo	Cambio	Precio	Transacción	Presentación
Nathan Steven D	COMPRA	+115,000	$0.18	06/04/2026	06/05/2026
Milligan Sandra	COMPRA	+115,000	$0.18	06/04/2026	06/05/2026
Cox Russell J.	COMPRA	+115,000	$0.18	06/04/2026	06/05/2026
Daniel Thomas O	COMPRA	+115,000	$0.18	06/04/2026	06/05/2026
Drynan Skye	COMPRA	+115,000	$0.18	06/04/2026	06/05/2026
Quisel John D	COMPRA	+115,000	$0.18	06/04/2026	06/05/2026
Christian Waage	VENTA	-70,000	$1.36	03/19/2026	03/20/2026
Giraudo Bryan	VENTA	-211,500	$2.16	03/19/2026	03/20/2026
Hasnain Faheem	VENTA	-47,000	$12.10	03/19/2026	03/20/2026
Smith Robert Paul JR	VENTA	-562,500	$2.88	03/19/2026	03/20/2026
Peterson Caryn	VENTA	-125,000	$0.84	03/19/2026	03/20/2026
Aranda Richard	VENTA	-157,500	$2.16	03/19/2026	03/20/2026
Christian Waage	COMPRA	+506,250	$2.88	01/02/2026	01/05/2026
Christian Waage	COMPRA	+84,500	Not reported	01/02/2026	01/05/2026
Peterson Caryn	COMPRA	+84,500	Not reported	01/02/2026	01/05/2026
Peterson Caryn	COMPRA	+506,250	$2.88	01/02/2026	01/05/2026
Aranda Richard	COMPRA	+93,750	Not reported	01/02/2026	01/05/2026
Aranda Richard	COMPRA	+562,500	$2.88	01/02/2026	01/05/2026
Smith Robert Paul JR	COMPRA	+93,750	Not reported	01/02/2026	01/05/2026
Smith Robert Paul JR	COMPRA	+562,500	$2.88	01/02/2026	01/05/2026

Sobre la compañía

Gossamer Bio, Inc.

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. The company was incorporated in 2015 and is headquartered in San Diego, California.

Fuente - Link

Competidores

CRVS FDMT KALV LXRX OLMA PRTA RAPT RGNX RIGL VTYX

Tamaño = capitalización · color = línea del gráfico

Rendimiento de peers · 1A

Top performers + empresa seleccionada

Ultimas Noticias

Gossamer Bio to Present at Cantor Global Healthcare Conference

Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment

GuruFocus

Gossamer Bio to Present at Cantor Global Healthcare Conference

SAN DIEGO--(BUSINESS WIRE)---- $GOSS--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Company will present at the Cantor Global Healthcare Conference to take place on September 9-11, 2026. Cantor Global Healthcare Conference Date / Time: September 9th,.

Business Wire

Gossamer Bio Announces Up to $250 Million Structured Private Placement, Including $150 Million of Committed Capital, to Fund Seralutinib Through Potential FDA Approval

Gossamer Bio, Inc. (Nasdaq: GOSS) (the âCompanyâ or âGossamerâ), a clinical-stage biopharmaceutical company focused on the development and commercializa

GuruFocus

Gossamer Bio Announces Up to $250 Million Structured Private Placement, Including $150 Million of Committed Capital, to Fund Seralutinib Through Potential FDA Approval

SAN DIEGO--(BUSINESS WIRE)---- $GOSS--Gossamer Bio, Inc. (Nasdaq: GOSS) (the “Company” or “Gossamer”), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that it has entered into a securities purchase agreement with certain new and existing institutional investors for a private placement financing.

Business Wire

Gossamer Bio (GOSS) Reports Q2 Loss, Tops Revenue Estimates

Gossamer Bio (GOSS) came out with a quarterly loss of $0.2 per share versus the Zacks Consensus Estimate of a loss of $0.1. This compares to a loss of $0.17 per share a year ago.

Zacks Investment Research

Sorpresas de ganancias

Período	Estimado	Real	Sorpresa
2026-05-18	-0.17	-0.2	-0.03
2026-03-17	-0.2	-0.21	-0.01
2025-11-05	-0.19	-0.21	-0.02
2025-08-05	-0.18	-0.17	0.01
2025-05-15	-0.18	-0.16	0.02
2025-03-13	-0.17	-0.15	0.02
2024-11-07	-0.18	-0.14	0.04
2024-08-12	0.23	0.22	-0.01
2024-05-07	-0.19	-0.19	0
2024-03-05	-0.2	-0.21	-0.01
2023-11-09	-0.2	-0.21	-0.01
2023-08-08	-0.49	-0.45	0.04